Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

FHS
March 11, 2024
12:55 pm

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.

Study finds link between industry payments to oncologists and non-recommended cancer treatments

Patients with cancer whose oncologist receives payments from industry appear more likely to receive some non-recommended and low value treatments, finds a US study published

October 26, 2023

Novel Drug OK’d for Ulcerative Colitis

The FDA approved mirikizumab (Omvoh) for the treatment of adults with moderately to severely active ulcerative colitis, manufacturer Eli Lilly announced on Thursday. The injectable

October 28, 2023

Ascension Restores EHR Access Florida, Alabama, Austin Markets After Cyberattack

What You Should Know: – Ascension announced it has restored EHR access in Florida, Alabama, and Austin markets affected by a recent cyberattack. – Ascension

June 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.